Download PDF

1. Company Snapshot

1.a. Company Description

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays.


The company's products include assay kits and other consumables such as reagents.In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services.The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation.


It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents.The company was formerly known as Digital Genomics, Inc.and changed its name to Quanterix Corporation in August 2007.


Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Show Full description

1.b. Last Insights on QTRX

Quanterix Corporation's recent performance was driven by the successful completion of its acquisition of Akoya Biosciences, creating a scaled leader in the early detection of disease for neurology, oncology, and immunology markets. This strategic move expands Quanterix's capabilities, enabling the company to measure biomarkers across the blood and tissue continuum. The acquisition is expected to drive growth and enhance the company's competitive position in the industry. Additionally, Quanterix's Q1 2025 earnings beat expectations, with a loss of $0.53 per share compared to the Zacks Consensus Estimate of a loss of $0.69.

1.c. Company Highlights

2. Quanterix Q4 2025: Growth Amid Organic Decline

Q4 2025 revenue reached $43.9 million, a 25% year‑over‑year increase, while organic revenue fell 22%. GAAP gross margin settled at 45.7%, within the 45% guidance range for 2026, and Non‑GAAP gross margin hit 50%, comfortably within the 49‑53% forecast. Adjusted EBITDA was a loss of $7.9 million, and EPS came in at –$0.38 versus the –$0.27 estimate.

Publication Date: Apr -10

📋 Highlights
  • Q4 Revenue Growth & Organic Decline:: Total revenue rose 25% YoY to $43.9M, but organic revenue fell 22% in Q4 2025.
  • Strong Cash Position:: The company holds $122M in cash and cash equivalents with no debt as of Q4 2025.
  • LucentAD Regulatory Milestones:: Achieved CMS reimbursement approval and FDA 510(k) premarket notification for Alzheimer’s diagnostic test.
  • 2026 Financial Targets:: Aims for $169–174M revenue and cash flow breakeven, with non-GAAP gross margin guidance of 49–53%.
  • Product Innovation:: Launched 13 new assays in 2025, with 501(k) submission for LucentAD expected to conclude by Q4 2026.

Revenue and Margin Dynamics

Revenue growth is driven by the launch of 13 new assays and the LucentAD Alzheimer's diagnostic, which secured CMS reimbursement approval and a 510(k) pre‑market notification, a milestone highlighted by CEO Everett Cunningham [Cunningham]. The company’s pipeline expansion and strategic focus on neurology, oncology, and immunology are expected to offset the organic decline.

Cash Position and Investment Outlook

3. NewsRoom

Card image cap

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Apr -17

Source: businesswire.com

Card image cap

Quanterix Debuts Content Innovation Engine at AACR 2026

Apr -15

Source: businesswire.com

Card image cap

Aberdeen Group plc Trims Stock Holdings in Quanterix Corporation $QTRX

Apr -10

Source: defenseworld.net

Card image cap

Quanterix Corporation Announces Date of 2026 Annual Meeting

Mar -27

Source: businesswire.com

Card image cap

Analyzing Quanterix (NASDAQ:QTRX) & IM Cannabis (NASDAQ:IMCC)

Mar -19

Source: defenseworld.net

Card image cap

Quanterix (NASDAQ:QTRX) vs. TREES (OTCMKTS:CANN) Head-To-Head Review

Mar -09

Source: defenseworld.net

Card image cap

Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript

Mar -03

Source: seekingalpha.com

Card image cap

Quanterix Corporation (QTRX) Reports Q4 Loss, Beats Revenue Estimates

Mar -02

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.00%)

6. Segments

Consumable and Other Product

Expected Growth: 14%

Quanterix Corporation's Consumable and Other Product segment growth of 14% is driven by increasing adoption of Simoa technology in life sciences research, expansion into new markets, and growing demand for ultrasensitive biomarker detection. Additionally, strategic partnerships and collaborations are fueling growth, as well as investments in product development and commercialization.

Instrument

Expected Growth: 12%

Quanterix Corporation's 12% growth is driven by increasing adoption of its Simoa technology in life sciences research, expansion into new markets such as infectious disease and oncology, and growing demand for precision medicine and diagnostics. Additionally, strategic partnerships and collaborations with pharmaceutical companies and research institutions contribute to the company's growth momentum.

Simoa Accelerator Lab Services

Expected Growth: 10%

Quanterix's Simoa Accelerator Lab Services growth is driven by increasing adoption of ultrasensitive biomarker detection in precision medicine, rising demand for early disease detection and diagnosis, and expansion into new therapeutic areas such as neurology and oncology, coupled with strategic partnerships and investments in digital health platforms.

Other Services

Expected Growth: 8%

Quanterix Corporation's Other Services segment growth is driven by increasing adoption of its Simoa technology, expansion into new markets, and growing demand for biomarker testing in drug development and precision medicine. Additionally, strategic partnerships and collaborations with pharmaceutical companies and research institutions contribute to the segment's growth.

Collaboration and License

Expected Growth: 18%

Quanterix Corporation's 18% growth in Collaboration and License is driven by increasing adoption of its Simoa technology, strategic partnerships with pharmaceutical and biotech companies, and expansion into new markets such as neurology and oncology. Additionally, the company's focus on developing novel biomarkers and assays is contributing to its growth.

7. Detailed Products

Simoa HD-1 Analyzer

A fully automated, benchtop immunoassay platform that enables ultra-sensitive detection of biomarkers in various sample types

Simoa Planar Array

A high-density, multiplexed assay platform for simultaneous detection of multiple biomarkers in a single sample

Simoa Homebrew Assays

Customizable, high-sensitivity assays for detection of specific biomarkers in various sample types

Simoa Services

Comprehensive assay development, validation, and testing services for pharmaceutical, biotechnology, and academic clients

8. Quanterix Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Quanterix Corporation operates in the life sciences industry, which is characterized by a moderate threat of substitutes. While there are alternative technologies available, Quanterix's proprietary Simoa technology provides a unique value proposition that differentiates it from competitors.

Bargaining Power Of Customers

Quanterix Corporation's customers are primarily pharmaceutical and biotechnology companies, which have limited bargaining power due to the specialized nature of Quanterix's products and services.

Bargaining Power Of Suppliers

Quanterix Corporation relies on a limited number of suppliers for its raw materials and components, which gives them some bargaining power. However, Quanterix's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.

Threat Of New Entrants

The life sciences industry has high barriers to entry, including significant capital expenditures and regulatory hurdles, which limits the threat of new entrants. Quanterix Corporation's proprietary technology and established customer base also provide a competitive advantage.

Intensity Of Rivalry

The life sciences industry is highly competitive, with several established players competing for market share. Quanterix Corporation faces intense competition from companies such as Illumina, Thermo Fisher Scientific, and Bio-Rad Laboratories, which could impact its market share and pricing power.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 10.68%
Debt Cost 10.97%
Equity Weight 89.32%
Equity Cost 10.97%
WACC 10.97%
Leverage 11.95%

11. Quality Control: Quanterix Corporation passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Artivion

A-Score: 4.7/10

Value: 4.8

Growth: 4.4

Quality: 5.2

Yield: 0.0

Momentum: 9.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Quanterix

A-Score: 3.4/10

Value: 8.6

Growth: 4.7

Quality: 4.8

Yield: 0.0

Momentum: 0.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
ZimVie

A-Score: 3.3/10

Value: 5.2

Growth: 2.3

Quality: 3.3

Yield: 0.0

Momentum: 8.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Bioventus

A-Score: 3.1/10

Value: 5.2

Growth: 3.3

Quality: 6.6

Yield: 0.0

Momentum: 1.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
MaxCyte

A-Score: 2.9/10

Value: 8.2

Growth: 2.2

Quality: 5.1

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Iridex

A-Score: 2.7/10

Value: 8.5

Growth: 1.8

Quality: 3.8

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.5$

Current Price

3.5$

Potential

-0.00%

Expected Cash-Flows